Lumos Diagnostics Raises Fresh Capital to Accelerate FebriDx Expansion

An announcement from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.

Lumos Diagnostics has reported the results of its non-underwritten Share Purchase Plan, which closed on 24 April 2026 and followed a A$20 million institutional placement completed in March. The company raised A$265,000 from eligible shareholders under the plan, including participation by two directors, with investors subscribing for 1,177,770 new shares at A$0.225 each.

Participants in the Share Purchase Plan will receive one free option for every two new shares, with the options exercisable at A$0.34 and expiring on 31 December 2027, and a large tranche of placement options is being issued on the same terms. Management says the strengthened capital position will support a significant expansion push for FebriDx in CLIA Waived settings across the U.S., aiming to extend the test’s reach to hundreds of thousands of locations and tens of millions of respiratory patients annually.

The company expects to issue the new shares, Share Purchase Plan options and placement options on 1 May 2026, with an additional block of options for participating directors to be put to shareholders for approval at an upcoming annual meeting. Lumos positions this capital raise as critical to maintaining strategic momentum in challenging market conditions and to advancing its mission of improving patient care while tackling antimicrobial resistance.

More about Lumos Diagnostics Holdings Ltd.

Lumos Diagnostics is a point-of-care diagnostics company focused on improving the diagnosis and management of acute infectious and inflammatory conditions. It develops and commercialises rapid, clinically actionable tests, such as its flagship FebriDx assay, combining proprietary technologies and scalable manufacturing to serve primary and acute care markets worldwide.

FebriDx is a rapid, 10-minute point-of-care test that helps clinicians distinguish between bacterial and non-bacterial respiratory infections. By enabling more targeted treatment decisions and potentially reducing unnecessary antibiotic prescribing, FebriDx aims to support better patient outcomes and address the growing challenge of antimicrobial resistance globally.

Average Trading Volume: 4,576,727

Technical Sentiment Signal: Sell

Current Market Cap: A$138.4M

For an in-depth examination of LDX stock, go to TipRanks’ Overview page.